Amgen’s $200M Plant a Booster Shot for Biopharm Sector

Source: PharmaManufacturing.com

Jun 04, 2013

Today Online

Singapore's standing as a manufacturing hub for bio-pharmaceutical products received a further boost yesterday with the groundbreaking of Amgen’s $200 million manufacturing facility. The 120,000-sq-ft plant, Amgen’s first in Asia, will be located at Tuas Biomedical Park along with industry majors such as Abbott and Novartis. The facility will manufacture both clinical and commercial products, initially focusing on producing monoclonal antibodies, a type of protein that can be used to treat certain cancers. Read the full story.
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments